Antiviral treatment and prognosis in patients undergoing maintenance hemodialysis due to hepatitis C virus.

Abstract

OBJECTIVES:

Maintenance hemodialysis (MHD) is one of the important renal replacement therapies for patients with end-stage renal disease. Hepatitis C virus (HCV) infection is a serious global public health problem. The proportion of MHD patients complicated with HCV infection and the risk of adverse prognosis are higher than those in the general population. Active antiviral treatment and prevention of reinfection is a combined treatment by nephrology and infection physicians. It is a widely accepted preventive measure to set hemodialysis buffer area for patients in treating HCV infection, but its effectiveness and safety still need to be further explored. Thus, the aim of this study is to explore the antiviral treatment and prognosis of MHD patients with HCV infection during hemodialysis.

METHODS:

A retrospective analysis for renal disease patients at 10 end-stage with long-term hemodialysis in the HCV area of the Blood Purification Center of Xiangya Hospital, Central South University. After standard antiviral drug treatment, the patient reached the cure standard for HCV infection. The buffer zone was set up in the Blood Purification Center by the Department of Nephrology of Xiangya Hospital since April 2017. Patients cured of HCV infection were transferred from the HCV area to the buffer zone for continuous dialysis, accompanied by monitoring serum HCV-RNA, anti-HCV antibody levels and changes in clinical biochemical indicators following the status of reinfection.

RESULTS:

Ten patients with HCV infection were finally cured after antiviral treatment, and there were no significant changes in clinical biochemical indicators before and after treatment. In the followed-up period after the transfer, the patient continued to be negative for HCV-RNA and positive for anti-HCV antibody.

CONCLUSIONS:

Direct antiviral therapy is safe and effective in MHD patients with HCV infection. Active antiviral therapy and transferring to the buffer area for dialysis are new and effective treatment modes for HCV patients during MHD.

• Authors: Weiwei Zhang, Qiongjing Yuan, Jianping Ning, Xia Li, Anhua Wu, Xiangcheng Xiao
• Journal: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences (Zhong Nan Da Xue Xue Bao Yi Xue Ban) Vol. 46 Issue 12 Pg. 1332-1337 (Dec 28 2021) ISSN: 1672-7347 [Print] China
• Vernacular Title: 维持性血液透析丙型肝炎病毒感染患者的抗病毒治疗及预后.
• PMID: 35232901 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents

Topics

• Antiviral Agents (therapeutic use)
• Hepacivirus (genetics)
• Hepatitis C (complications, drug therapy, epidemiology)
• Humans
• Kidney Failure, Chronic (complications, therapy)
• Prognosis
• Renal Dialysis
• Retrospective Studies